2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.06F.01 Survival Benefits of NGS in Advanced Lung Adenocarcinoma Vary by Populations and Timing of Examination

EP.06F.01 Survival Benefits of NGS in Advanced Lung Adenocarcinoma Vary by Populations and Timing of Examination

Pdf Summary

The study investigates the impact of next-generation sequencing (NGS) on survival in patients with advanced lung adenocarcinoma, focusing on different patient groups and examination timings. Conducted retrospectively, the study included 424 patients from December 2018 to January 2024, categorized into four groups based on NGS timing: treatment-naïve upfront (Group 1), treatment-naïve after exclusionary EGFR/ALK/ROS1 (Group 2), post-treatment without known driver mutations (Group 3), and post-tyrosine kinase inhibitor treatment with known mutations (Group 4).<br /><br />Key findings indicate that the identification and application of mutation-targeted treatments vary significantly across these groups. Group 1 showed the highest rate of targetable mutations (76.6%) and treatment application (68.0%), primarily detecting EGFR and ALK mutations. Groups 2, 3, and 4 exhibited lower rates of targetable mutations, ranging from 33.3% to 49.2%, with varying mutation profiles.<br /><br />Survival assessments revealed that patients receiving mutation-targeted treatments had significantly improved overall survival (OS), with a median of 59.9 months versus 43.1 months for non-treated patients. The most substantial survival benefit was observed in Group 1 (not reached vs. 40.4 months), followed by Group 2 (19.2 vs. 12.4 months). Although Groups 3 and 4 showed longer OS for treated patients (49.9 vs. 38.1 months and not reached vs. 19.3 months, respectively), the differences were not statistically significant.<br /><br />The study concludes that NGS and mutation-targeted therapy lead to varied survival benefits depending on the timing of examination and patient group. However, individuals receiving treatment for identified mutations consistently demonstrate longer survival, underscoring the importance of NGS in managing advanced lung adenocarcinoma.

Asset Subtitle

Po-Hsin Lee

Meta Tag

Speaker Po-Hsin Lee

Topic Pathology and Biomarkers

Keywords

next-generation sequencing

NGS

lung adenocarcinoma

mutation-targeted treatment

survival benefit

EGFR mutations

ALK mutations

tyrosine kinase inhibitor

patient groups

overall survival